Analysts at The Goldman Sachs Group began coverage on shares of Afya (NASDAQ:AFYA – Get Free Report) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set a “sell” rating and a $16.00 price target on the stock. The Goldman Sachs Group’s target price would suggest a potential downside of 1.11% from the stock’s current price.
Separately, UBS Group assumed coverage on shares of Afya in a research report on Friday, August 30th. They set a “neutral” rating and a $19.50 price objective on the stock.
Check Out Our Latest Analysis on Afya
Afya Stock Performance
Hedge Funds Weigh In On Afya
A number of large investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio purchased a new position in shares of Afya in the third quarter valued at about $34,000. Quarry LP purchased a new position in shares of Afya in the third quarter valued at about $75,000. Centiva Capital LP purchased a new position in shares of Afya in the third quarter valued at about $213,000. Quantbot Technologies LP increased its position in shares of Afya by 73.8% in the third quarter. Quantbot Technologies LP now owns 13,268 shares of the company’s stock valued at $226,000 after acquiring an additional 5,636 shares during the period. Finally, Lifestyle Asset Management Inc. increased its position in shares of Afya by 26.9% in the second quarter. Lifestyle Asset Management Inc. now owns 14,784 shares of the company’s stock valued at $261,000 after acquiring an additional 3,133 shares during the period. Hedge funds and other institutional investors own 88.02% of the company’s stock.
About Afya
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.
Featured Articles
- Five stocks we like better than Afya
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Tesla Poised to Hit Record Highs This Holiday Season
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- The Salesforce Rally is Just Getting Started: Here’s Why
- What is a Death Cross in Stocks?
- 3 Chip and Data Center Stocks That Can Keep Rising in 2025
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.